Development of a vaccine against pandemic influenza viruses: current status and perspectives.
The constant threat of a new influenza pandemic, which may be caused by a highly pathogenic avian influenza virus, necessitates the development of a vaccine capable of providing efficient, long-term, and cost-effective protection. Proven avenues for the development of vaccines against seasonal influenza as well as novel approaches have been explored over the past decade. Whereas significant insights are consistently being made, the generation of a highly efficient and cross-protective vaccine against the future pandemic influenza strain remains as the ultimate goal in the field. In this review, we re-examine these efforts and outline the scientific, political, and economic problems that befall this area of biotechnological research.
Ilyinskii
Petr O
PO
Cure Lab, Inc., Canton, Massachusetts 02021, USA. ilyinskii@curelab.com
Thoidis
Galini
G
Shneider
Alexander M
AM
D000818:Animals; D004196:Disease Outbreaks / Q000517:prevention & control; D006801:Humans; D007111:Immunity, Cellular; D016233:Immunotherapy, Active / Q000639:trends; D007252:Influenza Vaccines / Q000191:economics / Q000276:immunology*; D051379:Mice; D009975:Orthomyxoviridae / Q000276:immunology*; D009976:Orthomyxoviridae Infections / Q000276:immunology* / Q000517:prevention & control*; D019444:Vaccines, DNA / Q000191:economics / Q000276:immunology*
D007252:Influenza Vaccines; D019444:Vaccines, DNA